DUPIXENT is an add-on maintenance treatment for
adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and a high number of blood eosinophils (a type of white blood cell that may contribute to your COPD).
WHEN USED WITH COPD INHALERS,* DUPIXENT CAN:
View the possible side effects of DUPIXENT in patients with inadequately controlled chronic obstructive pulmonary disease. The most common side effects associated with DUPIXENT were:
*COPD inhalers are considered standard of care (SOC), which refers to a typical treatment approach prescribed by a healthcare professional for COPD.
†Assessed by SGRQ, a quality of life tool which measures COPD symptoms, physical activity, emotional well-being, and social functioning. In two trials,
51% of patients who received DUPIXENT + SOC experienced a quality of life improvement vs 43% and 47% with placebo + SOC. In one trial, results are
descriptive, no definitive conclusions can be made.
Prepare for your next appointment by answering the questions below and sharing them with your
pulmonologist. Your responses will help create a personalized treatment plan to help better manage your COPD.
Your answers and information are private to you. This data will not be stored or collected by DUPIXENT.
This is an interactive questionnaire to help you prepare for your doctor visit. You will be presented with questions one at a time. You can navigate between questions using the Back and Next buttons, and you don't need to answer every question before moving forward. Once you've completed all questions, you'll be able to get your personalized checklist.
Loading your checklist...
The DUPIXENT MyWay® Patient Assistance Program may be able to help eligible patients who do not have health insurance, are experiencing difficulty paying for your DUPIXENT treatment, or have Medicare Part D.‡
For those with commercial insurance, the DUPIXENT MyWay Copay Card may help eligible, patients pay as little as $0§ copay per fill of DUPIXENT.
If eligible, you can sign up online and your card will be sent via email. View full copay card Terms & Restrictions.
‡ Eligible commercial patients and Medicare patients without the Part D (pharmacy) benefit may receive free shipments of up to an 84-day supply of DUPIXENT (for up to 12 months). Patients may reapply after 12 months if they still meet the eligibility criteria. Patients with Medicare Part D who meet eligibility criteria must reapply for the Patient Assistance Program each calendar year, or by December 31st for eligibility consideration for the following year. The assistance period for Medicaid patients varies based on the eligibility criteria. Please note that DUPIXENT MyWay reserves the right to make eligibility determinations, monitor participation, ensure equitable product availability, and modify or discontinue the DUPIXENT MyWay Patient Assistance Program at any time without notice.
§ Subject to the program maximum per patient per calendar year. Approval is not guaranteed. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs, including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed, or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients’ out-of-pocket costs. The program is intended to help patients afford DUPIXENT. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms. Additional terms and conditions apply.
The Patient Brochure can help you better understand how DUPIXENT may help
improve your breathing and relieve COPD symptoms by reducing flare-ups.
Sign up to receive DUPIXENT emails and resources
providing more information on how DUPIXENT works,
cost and coverage, accessing DUPIXENT, supplemental
injection support, and more, like: